ReviewClinical and molecular hepatology2023
Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease.
Review in Clinical and molecular hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 91 citations in OpenAlex.
- Gut microbial dynamics and antibiotic resistance during rifaximin therapy in severe cirrhosis: a ProPILA-Rifax ancillary study.Frontiers in cellular and infection microbiology · 2026Trial
- The effects of ellagic acid in metabolic dysfunction-associated steatotic liver disease (MASLD) patients: a randomized, add-on, double-blind, controlled trial.Inflammopharmacology · 2025Trial
- The global burden of metabolic and alcohol-associated liver disease (MetALD).Hepatology communications · 2026Review
- Circadian Blood Pressure Patterns in Adults with Moderate-to-Severe Hepatic Steatosis: A Prospective Ambulatory Blood Pressure Monitoring Study.Journal of clinical medicine · 2026Article
- Article
- Burden of cardiovascular complications in steatotic liver disease in the United States.Clinical and molecular hepatology · 2026Article
- Biological age acceleration and extrahepatic multimorbidity in U.S. adults with metabolic dysfunction-associated steatotic liver disease: a national cross-sectional study.Clinical and experimental hepatology · 2026Article
- Association of the C-reactive protein-triglyceride glucose index with all-cause and cardiovascular mortality among U.S. adults with metabolic dysfunction-associated steatotic liver disease: a national cohort study.Cardiovascular diabetology · 2026Article
- Integrated lifestyle management to mitigate MASLD risk in patients with chronic kidney disease: a prospective cohort study.Journal of translational medicine · 2026Article
- Subtype-specific associations of steatotic liver disease with gastric and esophageal cancers: a nationwide cohort study.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026Article
- Association between dietary amino acid intake and the risk of metabolic dysfunction-associated steatotic liver disease.Journal of advanced research · 2026Article
- Unveiling the Burden of Steatotic Liver Disease: Mortality Risks by Subtype and Fibrosis Stage in a Nationwide Cohort.Liver international : official journal of the International Association for the Study of the Liver · 2026Observational
- Association between UMAP-identified body composition phenotypes and metabolic dysfunction-associated steatotic liver disease in the general population of China.Frontiers in nutrition · 2026Article
- Sex-specific differences in the prognostic value of METS-IR for long-term outcomes in patients with MASLD and advanced liver fibrosis: a nationwide study.European journal of medical research · 2025Article
- Quick glance at 'metabolic dysfunction associated steatotic liver disease' therapeutics: Targets, trials, and trends.World journal of gastrointestinal pharmacology and therapeutics · 2025Review
- Comparison of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Steatotic Liver Disease.Gut and liver · 2025Article
- Article
- Current burden of MASLD, MetALD, and hepatic fibrosis among US adults with prediabetes and diabetes, 2017-2023.Clinical and molecular hepatology · 2025Article
- The Burden of Nonmalignant Metabolic Dysfunction-Associated Steatotic Liver Disease in the Western Pacific Region: A Systematic Analysis From 1990 to 2021.Food science & nutrition · 2025Article
- ECM formation and degradation during fibrosis, repair, and regeneration.npj metabolic health and disease · 2025Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the United States and worldwide. Though nonalcoholic fatty liver per se may not be independently associated with an increased risk for all-cause mortality, it is associated with a number of harmful metabolic risk factors, such as type 2 diabetes mellitus, hyperlipidemia, obesity, a sedentary lifestyle, and an unhealthy diet. The fibrosis stage is a predictor of all-cause mortality in NAFLD. Mortality in individuals with NAFLD has been steadily increasing, and the most common cause-specific mortality for NAFLD is cardiovascular disease, followed by extra-hepatic cancer, liver-related mortality, and diabetes. High-risk profiles for mortality in NAFLD include PNPLA3 I148M polymorphism, low thyroid function and hypothyroidism, and sarcopenia. Achieving weight loss through adherence to a high-quality diet and sufficient physical activity is the most important predictor of improvement in NAFLD severity and the benefit of survival. Given the increasing health burden of NAFLD, future studies with more long-term mortality data may demonstrate an independent association between NAFLD and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.